Amag price target lowered to $14 from $17 at Cantor Fitzgerald

Cantor Fitzgerald analyst Matthew Lillis lowered his price target for Amag Pharmaceuticals to $14 from $17 saying failure of the post-approval Makena trial is a “clear setback for the company.” The trial result reinforces the importance of the next 12-18 months for Amag to demonstrate that existing and pipeline assets can adequately replace lost Makena revenue, Lillis tells investors in a research note. He reiterates a Neutral rating on the shares.
https://thefly.com/landingPageNews.php?id=2879011